Key Insights

Highlights

Success Rate

76% trial completion

Published Results

13 trials with published results (25%)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 49/100

Termination Rate

17.3%

9 terminated out of 52 trials

Success Rate

75.7%

-10.8% vs benchmark

Late-Stage Pipeline

17%

9 trials in Phase 3/4

Results Transparency

46%

13 of 28 completed with results

Key Signals

13 with results76% success

Data Visualizations

Phase Distribution

43Total
Not Applicable (5)
Early P 1 (1)
P 1 (14)
P 2 (14)
P 3 (9)

Trial Status

Completed28
Terminated9
Recruiting7
Withdrawn5
Active Not Recruiting2
Unknown1

Trial Success Rate

75.7%

Benchmark: 86.5%

Based on 28 completed trials

Clinical Trials (52)

Showing 20 of 20 trials
NCT03258567Phase 2Recruiting

Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas

NCT02402244Recruiting

Project: Every Child for Younger Patients With Cancer

NCT00092222Phase 2Active Not RecruitingPrimary

Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

NCT02861417Phase 2Active Not Recruiting

Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant

NCT04883437Phase 2Recruiting

Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas

NCT00033475Phase 3CompletedPrimary

Reduced Immunosuppressive Therapy With or Without Donor White Blood Cells in Treating Patients With Lymphoproliferative Disease After Organ Transplantation

NCT06630104Not ApplicableRecruitingPrimary

Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)

NCT01137643Recruiting

Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer

NCT00935090Recruiting

3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer

NCT01137825Recruiting

Registry of Older Patients With Cancer

NCT00001379Phase 2Completed

Treatment and Natural History Study of Lymphomatoid Granulomatosis

NCT01000753Completed

Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma

NCT00278200Phase 1TerminatedPrimary

Vaccine Therapy For Patients Being Considered For Organ Transplant Who Are at Risk For PTLD

NCT00900120Withdrawn

Collecting and Storing Blood Samples From Patients With Cancer

NCT00424242Early Phase 1Completed

Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases

NCT00726830Not ApplicableTerminated

Methadone, Morphine, or Oxycodone in Treating Pain in Patients With Cancer

NCT00070382Phase 3Completed

Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer

NCT00093704Phase 1Terminated

Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

NCT00750009Phase 3Completed

Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial

NCT01447056Phase 1Completed

Most Closely HLA-Matched CTLs for Relapsed Epstein Barr Virus(EBV)-Associated Diseases

Scroll to load more

Research Network

Activity Timeline